ArticleBiochemistry and biophysics reports2025
PepLess: A computational tool developed to optimize SPOT synthesis and analyze related immunoassay data.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SPOT synthesis is a simple and relatively inexpensive technique for synthesizing a large number of peptides on a cellulose membrane. However, this method becomes exhaustive and impractical when handling a large quantity of sequences with diverse specifications, often resulting in the generation of redundant peptides. Addressing this challenge, we present PepLess, an innovative computational tool designed to analyze multiple sequences simultaneously, thereby reducing the utilization of spot synthesis membranes. By avoiding the production of redundant peptides, PepLess offers a substantial improvement in efficiency and cost-effectiveness, minimizing both expenses and equipment usage. This work outlines the challenges associated with excessive peptide generation, introduces the functionality and benefits of PepLess, and concludes with validation through a case study employing Peruvian-origin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.